Sanofi India

Dividend stocks: BPCL, NTPC, CAMS, 14 others to remain in spotlight today

Dividend stocks today: Here is the complete list of stocks to remain in focus during today's trading following their announcement of interim dividends.

Cash in on dividends! Coal India, NTPC, 26 others go ex-date next week

Dividend stocks: Here's the complete list of stocks that will remain in focus next week, following their dividend announcements, along with key details

Emcure Pharma, Sanofi India shares edge higher; what's behind the move?

Emcure Pharma stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5 as the company announced a distribution and promotion partnership with Sanofi India

Emcure enters distribution agreement with Sanofi for diabetes drugs

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes

Stocks to watch today, May 15: Tata Power, Eicher, SBI, JSW Energy, Godfrey

In the previous trading session, Sensex gained 182.34 points, or 0.22 per cent, to settle at 81,330.56 level. The Nifty50, meanwhile, closed 88.55 points, or 0.36 per cent higher at 24,666.90 level.

Sanofi India Q4 results: Profit falls 12.5% to ₹119.5 cr, revenue up 4.9%

Sanofi India's Q4FY25 profit declined 12.5% Y-o-Y to ₹119.5 crore, while revenue rose 4.9%; operating profit improved 27% on better efficiency, says CFO

Investors rush to buy Sanofi India shares ahead of ex-dividend date; detail

The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible

Last chance: Sanofi India, Muthoot Finance to go ex-dividend on April 25

The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible

PVR Inox, Crompton, IEX: 5 smallcap stks see Death Cross; can dip up to 13%

Technically, the term 'Death Cross' indicates a weak set-up as the stock's 50-day moving average has dropped below the long-term 200-day moving average.

Nehal Vora reappointed MD and CEO of CDSL; SCHIL makes trading debut

Shares of CDSL last closed at Rs 1,382, up 0.25 per cent, valuing the company at Rs 28,879 crore

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

Sanofi India turns ex-date for healthcare biz demerger; hits 5% upper limit

Each member of Sanofi India holding 1 equity share in Sanofi India as on the Record Date i.e. June 13, 2024 shall entitled to receive 1 equity share of Sanofi Consumer Healthcare India.

Stocks to watch on May 14: Shriram Finance, Zomato, DLF, TCS, Maruti Suzuki

Shriram Finance announced that board has approved the sale of its housing finance subsidiary Shriram Housing Finance to Warburg Pincus for Rs 4,630 crore

Novavax signs Covid-19 license deal with Sanofi, secures business viability

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Sanofi India introduces diabetes drug 'Soliqua' at Rs 1,850 per pen

Sanofi reported that in India, over 100 million individuals are grappling with type 2 diabetes and its associated complexities

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Sanofi, Cipla join hands to expand reach of CNS portfolio in India

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

Sanofi India, Emcure Pharma announce exclusive distribution partnership

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business